期刊文献+

APTT ACTIN试剂和APTT ACTIN FSL试剂临床应用比较 被引量:2

下载PDF
导出
摘要 目的评价活化部分凝血活酶时间(APTT)检测试剂APTT ACTIN FSL的性能,并与APTT ACTIN试剂比较临床诊断效能。方法按照美国临床和实验室标准协会(Clinical and Laboratory Standards Institute,CLSI)EP5-A2、EP9-A2文件及国家卫生健康委员会WS/T406-2012文件等,对APTT ACTIN FSL试剂进行正确度、精密度、携带污染率、仪器间比对、批号间比对等性能评价并建立参考区间,同时评价APTT ACTIN FSL试剂和APTT ACTIN试剂对凝血因子、狼疮抗凝物(LA)的敏感性,并建立普通肝素抗凝治疗范围(HTR)。结果 APTT ACTIN FSL试剂在CS5100和CA7000 2种仪器上,5份CAP室间质评物偏差<4.00%;3个水平质控品的重复性为0.38%~1.83%,期间精密度为1.22%~3.57%;携带污染率分别为-1.58%和0.62%;参考区间分别为23.3~32.5 s和24.2~31.6 s。两批号间比对相对偏差(%)均在±5.0%以内,相关系数为0.999。APTT ACTIN试剂和APTT ACTIN FSL试剂对FⅧ、FⅨ和FⅪ各因子敏感性分别为45.0%、34.1%和53.8%,以及57.6%、39.5%和46.6%。2种试剂对76例阳性LA样本阳性检出率分别为40.8%和56.6%,卡方检验显示二者间差异有统计学意义(χ^2=34.432,P=0.000);2种试剂对52例中至强阳性样本阳性检出率分别为55.8%和73.1%,卡方检验显示二者间差异有统计学意义(χ^2=18.364,P=0.000)。2种试剂建立的HTR分别为58.3~124.4 s和42.8~69.2 s,2例患者动态监测样本结果趋势一致。结论 APTT ACTIN FSL试剂性能良好,对凝血因子和LA敏感性满足临床需求。实验室应建立或验证不同检测系统的参考区间及HTR,并在试剂更换时与临床有效沟通。
出处 《临床检验杂志》 CAS 2019年第6期456-460,共5页 Chinese Journal of Clinical Laboratory Science
  • 相关文献

参考文献2

二级参考文献27

  • 1中国合格评定国家认可委员会.CNAS-CL02:医学实验室质量和能力认可准则[EB/OL ]. (2013-11-22 ) [2014-11-01 ].http ://www. cnas. org. cn/images/rkgf/sysrk/jbzz/2013/12/20/lC3A61EEC69A825B0FD01ECD986D9B78.pdf.
  • 2Simko R J, Tsung FF, Stanek EJ. Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin [ J ]. Ann Pharmacother, 1995, 29 ( 10 ) : 1015-1021.
  • 3Fritsma GA, Dembitzer FR, Randhawa A, et al. Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization [ J ], Am J Clin Pathol, 2012, 137(6) :904-908. DOI:IO. 1309/AJCP3J1ZKYBFQXJM.
  • 4Olson JD, Cunningham MT, Higgins RA, et al. D-dimer: simple - test, tough problems[ J]. Arch Pathol Lab Med, 2013, 137 (8) : 1030-1038. DOI : 10. 5858/arpa. 2012-0296-CP.
  • 5Will A. Neonatal haemostasis and the management of neonatal thrombosis[ J]. Br J Haematol, 2015, 169 ( 3 ) : 324-332. DOI: 10. llll/bjh. 13301.
  • 6Favaloro E J, Franchini M, Lippi G. Aging hemostasis: changes to laboratory markers of hemostasis as we age - a narrative review [ J]. Semin Thromb Hemost, 2014, 40 (6) : 6214533. DOI: 10. 1055/s-0034-1384631.
  • 7Franchini M, Crestani S, Frattini F, et al. ABO blood group and yon Willebrand factor: biological implications[ J]. Clin Chem Lab Med, 2014, 52(9):1273-1276. DOI:10. 1515/cclm-2014-0564.
  • 8Chen Q, Shou W, Wu W, et al. Biological and analytical variations of 16 parameters related to coagulation screening tests and the activity of coagulation factors [ J ]. Semin Thromb Hemost, 2015,41 (3) :336-341. DOI : 10. 1055/s-0034-1543994.
  • 9Shou W, Chen Q, Wu W, et al. Biological Variations of Lupus Anticoagulant, Antithrombin, Protein C, Protein S, and yon Willebrand Factor Assays [ J 1. Semin Thromb Hemost, 2016, 42 ( 1 ) :87-92. DOI:10. 1055/s-0035-1552588.
  • 10Lippi G, Salvagno GL, Montagnana M, et al. Quality standards for sample collection in coagulation testing [ J ]. Semin Thromb Hemost, 2012, 38 ( 6 ) : 565-575. DOI: 10. 1055/s-0032- 1315961.

共引文献191

同被引文献11

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部